Maravai Lifesciences Holdings (MRVI) Shares Outstanding (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Shares Outstanding (Entity) of $147.5 million for Q1 2026, up 2.46% year-over-year from $144.0 million in Q1 2025, and up 1.49% quarter-over-quarter from $145.3 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Shares Outstanding (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $147.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.46% year-over-year to $147.5 million; the TTM figure through Mar 2026 stood at $147.5 million (up 2.46% YoY), while the FY2025 annual figure was $145.3 million, up 2.36% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $147.5 million, up from $145.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $147.5 million in Q1 2026, with the low at $131.5 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $132.7 million (2024), against an average of $137.5 million.
- Peak annual rise in Shares Outstanding (Entity) reached 36.05% in 2022, while the deepest fall reached 0.09% in 2022.
- Maravai Lifesciences Holdings' Shares Outstanding (Entity) stood at $131.7 million in 2022, then rose by 0.41% to $132.2 million in 2023, then rose by 7.37% to $142.0 million in 2024, then rose by 2.36% to $145.3 million in 2025, then advanced by 1.49% to $147.5 million in 2026.
- Business Quant data shows MRVI's Shares Outstanding (Entity) at $147.5 million in Q1 2026, $145.3 million in Q4 2025, and $144.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 148.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 148.00 Mn |
| Mar 31, 2026 | 146.43 Mn |
| Dec 31, 2025 | 144.36 Mn |
| Sep 30, 2025 | 144.68 Mn |
| Jun 30, 2025 | 144.24 Mn |
| Mar 31, 2025 | 143.43 Mn |
| Dec 31, 2024 | 137.91 Mn |
| Sep 30, 2024 | 141.56 Mn |
| Jun 30, 2024 | 135.84 Mn |
| Mar 31, 2024 | 132.33 Mn |
| Dec 31, 2023 | 131.92 Mn |
| Sep 30, 2023 | 131.93 Mn |
| Jun 30, 2023 | 131.86 Mn |
| Mar 31, 2023 | 131.74 Mn |
| Dec 31, 2022 | 131.55 Mn |
| Sep 30, 2022 | 131.54 Mn |
| Jun 30, 2022 | 131.52 Mn |
| Mar 31, 2022 | 131.49 Mn |
| Dec 31, 2021 | 114.79 Mn |
| Sep 30, 2021 | 118.43 Mn |